Mr.Charles

I only give one advice, do not let others do your thinking for you.

[Mr.Charles @MrChaarless]

Short squeeze inbound! $SINCH #StockTwits #StockMarketwin

[Andrei @BostonDrei]

$CLPT PRISM Neuro Laser is going to be huge. Top and center even at the conference.

Clinical Laserthermia Systems $CLS.b partnership is really special in terms of effectiveness and features, best in class.

[ClearPointNeuro @ClearPointNeuro]

#ClearPoint Neuro Announces Promising Results from Brain Tumor Laser Therapy Study to be Presented at the CNS Annual Meeting in Los Angeles at Booth 545 - Read More Here: https://t.co/sizcZ7jua4
#2025CNS #CLPT #LITT #LaserTherapy #Glioblastoma #NeuroOncology #MedTech

[Peter Mantas @peter_mantas]

$CLS.b Good to see the new 1.5T approval. Going full neuro was the right and obvious move. $CLPT.

[Mr.Charles @MrChaarless]

https://t.co/x6ErxdM1vX

[Mr.Charles @MrChaarless]

A Milestone Moment for Clinical Laserthermia Systems & ClearPoint Neuro
Clinical Laserthermia Systems ($CLS.B) & ClearPoint Neuro ($CLPT) have submitted an FDA application to expand ClearPoint Prism™ to 1.5T MRI guidance. This is a pivotal step for neuro laser therapy. #MedTech

[Mr.Charles @MrChaarless]

This submission isn’t just about one product—it’s about transforming neurosurgery. Approval could accelerate adoption, drive revenue, and position $CLS.B & $CLPT as leaders in a booming field. Investors, take note! #HealthcareInnovation

[Mr.Charles @MrChaarless]

@peter_mantas For those who wonder.. just read 👇
https://t.co/c1ZpXR9Wie

[Mr.Charles @MrChaarless]

HUGE news for $CLS.B!
New updated clinical guidelines now officially recommend Laser Interstitial Thermal Therapy (LITT) for patients with metastatic brain tumors & radiation necrosis.
This is not just good — it's transformational.
Let’s break it down. 👇

[Mr.Charles @MrChaarless]

This is the kind of catalyst that shifts sentiment, boosts revenue potential, and builds long-term strategic value.

#CLS #LITT #NeuroOncology #Medtech $CLS.B $CLPT #cancer

[Mr.Charles @MrChaarless]

HUGE news for $CLS.B!
New updated clinical guidelines now officially recommend Laser Interstitial Thermal Therapy (LITT) for patients with metastatic brain tumors & radiation necrosis.
This is not just good — it's transformational.
Let’s break it down. 👇

[Socrates @Infosocratess]

News CLS 🤩

https://t.co/rZBT1TkU0e

[Mr.Charles @MrChaarless]

Radiation necrosis and metastatic brain tumors are growing clinical challenges. There’s high unmet need. CLS’s and Clearpoint´s LITT platform just became part of the solution — by guideline. That’s huge!

[Mr.Charles @MrChaarless]

@ValueHunter7 Indeed, some downward pressaure from the directed new issue. Should be over soon and I expect the stock to make som significant gains ahead. I expect to see @peter_mantas to do some of his magic as well ;)

[Mr.Charles @MrChaarless]

CLS restructures to focus entirely on its successful neurosurgery business. A sharper focus paves the way for sustainable growth, value creation and innovation in medical technology. #neurosurgery #medtech #aktier $CLSB $CLPT

https://t.co/X0DFiT7a3P